Hair loss can be caused by hormones, illness, autoimmune disorders, or vitamin deficiencies, and treatments vary depending on the type.
July 2022 in “Journal of Investigative Dermatology” IL-15 helps maintain hair growth and protects the immune status of hair follicles.
December 2021 in “Journal of The American Academy of Dermatology” COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.
January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
August 2017 in “Journal of biotechnology” Topical corticosteroids are the best initial treatment for children with Alopecia Areata.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
January 2022 in “Clinical Cases in Dermatology” Androgenetic alopecia, a common hair loss condition, can be treated with topical minoxidil, oral finasteride, or oral spironolactone, and new treatments like platelet-rich plasma, low-level laser therapy, and janus-kinase inhibitors are being explored.
3 citations,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
1 citations,
August 2019 in “Australasian journal of dermatology” Immunotherapy can help treat severe alopecia areata.
December 2023 in “Aesthetic Cosmetology and Medicine” COVID-19 can cause hair loss, but specialists can help treat it.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
85 citations,
October 2015 in “Proceedings of the National Academy of Sciences of the United States of America” NF-κB is crucial for zebrafish heart repair, affecting heart cell growth and repair processes.
70 citations,
February 2015 in “Expert Opinion on Drug Discovery” Topical drugs and near-infrared light therapy show potential for treating alopecia.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
23 citations,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
21 citations,
June 2017 in “Journal of The American Academy of Dermatology” Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
15 citations,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” Platelet-Rich Plasma (PRP) could potentially help regrow hair in people with Alopecia Areata, but more research is needed to confirm its effectiveness.
11 citations,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
9 citations,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.